A novel breast cancer imaging technology developed in Sherbrooke, Quebec, promises faster and more precise detection of metastases throughout the body. Spearheaded by Dr. Éric Turcotte and supported by a $50,000 joint funding initiative from the Fondation du CHUS and the Quebec Cancer Foundation, the method uses a cyclotron-produced tracer to pinpoint lesions within minutes.
Cyclotron-Produced Tracer Cuts Scan Times
The diagnostic procedure relies on the administration of a tracer by cyclotron. Once injected into the patient, the tracer allows for the rapid detection of breast cancers. One hour after the injection, it takes 10 minutes to determine the precise location of metastases.
This technique allows clinicians to detect lesions regardless of their location, whether under the arm, hidden in a bone, or hidden in a lung. Dr. Éric Turcotte, head of service and research lead at the medical imaging and radiation sciences department at the Université de Sherbrooke, noted that they can always locate them with precision.
Alleviating Psychological Toll for Patients
For patients navigating suspected malignancy, the wait to obtain biopsy results creates severe psychological distress. Marie-Andrée Quirion, a breast cancer survivor, experienced a five-to-six-week wait for biopsy results during her own diagnosis, describing the interval as an extremely difficult period dominated by intense worry for her family and children.
Implementing the Sherbrooke imaging protocol aims to compress these diagnostic timelines. Dr. Brigitte Guérin, a researcher and professor at the CHUS Research Institute, emphasized that the discovery—originally initiated by Dr. Johannes Van Lier of the Université de Sherbrooke—establishes a crucial pathway for accurate initial diagnosis and subsequent treatment monitoring.
Philanthropic Backing Funds Initial Access
To bridge the gap between clinical innovation and universal provincial deployment, regional health charities stepped in with immediate financial backing. The Fondation du CHUS and the regional center of the Quebec Cancer Foundation swiftly allocated $50,000 to grant several hundred women free access to the diagnostic procedure, according to Sandra Asselin, director of the regional center of the Quebec Cancer Foundation.
While philanthropic funding covers these initial hundreds of interventions, research leadership aims to secure permanent provincial subsidization. Dr. Turcotte indicated an expectation that within a window of one and a half to two years, the public system could take over.
This regional rollout coincides with broader public health communications observed during Breast Cancer Awareness Month in October. Government bodies, medical associations, and organizations such as the Quebec Breast Cancer Foundation coordinate campaigns to disseminate information regarding screening protocols and risk factors.
National Incidence and Epidemiological Backdrop
The introduction of advanced imaging techniques arrives against a backdrop of high national disease incidence. Canadian Cancer Society projections estimate that in 2026, over one-quarter of all new cancer diagnoses among women involve breast cancer, translating to an average of 89 confirmed cases daily nationwide.
Although the mortality rate has declined since its historical peak in 1986, epidemiological data indicates that approximately one in eight Canadian women will develop breast cancer over the course of her lifetime.
References
Canadian Cancer Society. (2026). Breast Cancer Statistics and Projections. Université de Sherbrooke. CHUS Research Institute. Molecular Tracers and Cyclotron Applications in Oncology.
Related reading
